Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
Amgen Inc. fell $1.45 or. 9 percent, to $153.71. Biogen Idec fell $4.30 or 1.2 percent, to $344.45. Celgene Corp. fell $1.82 or 1.5 percent, to $119.28.
SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....
Amgen Inc. rose$. 02 or percent, to $155.16. Biogen Idec fell $3.99 or 1.1 percent, to $348.75. Celgene Corp. rose $1.12 or. 9 percent, to $121.10.
Amgen Inc. rose$. 26 or. 2 percent, to $155.40. Biogen Idec fell $1.08 or. 3 percent, to $351.66. Celgene Corp. rose $1.74 or 1.5 percent, to $121.72.
Amgen Inc. fell$. 01 or percent, to $155.13. Biogen Idec rose $1.21 or. 3 percent, to $353.95. Celgene Corp. rose$. 61 or. 5 percent, to $120.59.
Investors are watching closely to see how insurers decide to cover these drugs, which cost tens of thousands of dollars per treatment, after AbbVie Inc started a competitor to Gilead Sciences' breakthrough hepatitis C treatment. Express Scripts, the largest pharmacy benefit manager in the United States, dropped Gilead Sciences hepatitis C drugs from its main...
Amgen Inc. fell $1.08 or. 7 percent, to $155.14. Biogen Idec rose $4.90 or 1.4 percent, to $352.74. Celgene Corp. rose $2.98 or 2.5 percent, to $119.98.
One minute it's up, the next minute it's down. Jim Cramer gives two important tips for navigating the rough seas of a volatile market.
Apple Inc. rose 1.9 percent to $111.36 with 34,715,400 shares traded. Arena Pharmaceuticals Inc. rose 6.2 percent to $6.00 with 16,629,800 shares traded. Cisco Systems Inc. rose 1.3 percent to $28.41 with 19,030,700 shares traded.
Amgen Inc. rose $1.17 or. 7 percent, to $157.39. Biogen Idec rose $11.03 or 3.2 percent, to $358.87. Celgene Corp. rose $6.08 or 5.2 percent, to $123.08.
Amgen Inc. rose $4.48 or 2.9 percent, to $160.70. Biogen Idec rose $6.78 or 1.9 percent, to $354.62. Celgene Corp. rose $4.31 or 3.7 percent, to $121.31.
SAN FRANCISCO, Jan 12- Eli Lilly and Co said on Monday that U.S. insurers are increasing pressure on the price of diabetes medications as they switch coverage from certain drugs to others to trim costs. "We've definitely seen increased price competition, more by payers than the companies themselves," Lilly Chief Financial Officer Derica Rice said on Monday in an...
Traders on CNBC's "Fast Money" outlined their strongest plays in the ever-volatile biotechnology space.
Amgen Inc. rose$. 49 or. 3 percent, to $156.22. Biogen Idec rose $5.50 or 1.6 percent, to $347.84. Celgene Corp. rose $3.33 or 2.9 percent, to $117.00.
Amgen Inc. rose$. 95 or. 6 percent, to $156.68. Biogen Idec rose $6.71 or 2.0 percent, to $349.05. Celgene Corp. rose $2.73 or 2.4 percent, to $116.40.
Amgen Inc. rose $1.19 or. 8 percent, to $156.92. Biogen Idec rose $3.66 or 1.1 percent, to $346.00. Celgene Corp. rose $1.88 or 1.7 percent, to $115.55.
Shares of Tekmira Pharmaceuticals soared Monday after the Canadian drugmaker said it would buy privately held OnCore Biopharma to form a team focused on developing a hepatitis B cure. Other drugmakers like Gilead Sciences Inc. have developed new treatments for hepatitis C that have been hailed as breakthroughs in curing the liver-destroying virus.
Some of Friday's midday movers:
History says the best play is to buy biotech stocks the day before the JPMorgan meeting starts and hold until the end.
*Bed, Bath& Beyond stumbles after results, outlook. Nonfarm payrolls rose in December, topping Wall Street expectations while November's surprising gain was also revised higher. But the one really puzzling thing is the lack of any wage growth and in fact, wage decline, in December, "said David Kelly, chief global strategist for JPMorgan Funds in New York.